Abstracts tagged "Interleukins"

Abstract Number: LB01 • ACR Convergence 2025
Low-dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: a double-blind, randomised, placebo-controlled, phase IIb trial
Xia Zhang¹, Ruiling Feng¹, Zhanguo Li² and Jing He¹, ¹Peking University People's Hospital, Beijing, China (People's Republic), ²Peking Univeristy People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Low-dose Interleukin-2 (Ld-IL2) has shown therapeutic effect in autoimmune diseases, particularly systemic lupus erythematosus (SLE). Various doses from 0.33 to 3.0 million units of…
Abstract Number: LB08 • ACR Convergence 2025
Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study
Philip Mease¹, Frank Behrens², Alan Kivitz³, Edit Drescher⁴, Piotr Klimiuk⁵, Howard Sofen⁶, Nehad Soloman⁷, Shephard Mpofu⁸, Fredrik Frejd⁹ and Peter Taylor¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington, ²Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ³Altoona Arthritis and Osteoporosis Center, Altoona Center for Clinical Research, Duncansville, Pennsylvania, ⁴Vital Medical Center Rheumatology, Veszprém, Hungary, ⁵Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland, ⁶Department of Medicine/Dermatology, David Geffen UCLA School of Medicine, Los Angeles, California, ⁷Midwestern University Arizona College of Osteopathic Medicine and Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona, ⁸ACELYRIN, INC., Agoura Hills, California, ⁹Affibody Medical AB, Solna, Sweden, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: PsA is a chronic, systemic, inflammatory musculoskeletal disease in which dysregulated IL-17A activity plays a pivotal role in disease pathogenesis. Izokibep (IZO) is an…
Abstract Number: 0090 • ACR Convergence 2025
Interleukin-36β modulates the progression of rheumatoid arthritis by altering the behavior of rheumatoid arthritis synovial fibroblasts
Marie Svenja Kümmel¹, Mona Arnold-Gräf², Selina Ohl², Klaus Frommer³, Nils Schulz⁴, Stefan Rehart⁵, Ulf Müller-Ladner³ and Elena Neumann³, ¹Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Gießen, Germany, ²Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Bad Nauheim, Germany, ³Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Bad Nauheim, Hessen, Germany, ⁴Kerkchoff Klinik, Dep. of rheumatology, Bad Nauheim, Germany, ⁵Agaplesion Markus Hospital, Frankfurt, Hessen, Germany
Background/Purpose: Rheumatoid arthritis synovial fibroblasts (RASF) play a central role in driving inflammation and promoting cartilage degradation in Rheumatoid arthritis (RA). In our study, we…
Abstract Number: 0577 • ACR Convergence 2025
Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
Laure Gossec¹, Mohamed Sharaf², Xenofon Baraliakos³, mitsumasa kishimoto⁴, Ruben Queiro⁵, Ennio Lubrano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Karissa Lozenski⁹, Enrique R. Soriano¹⁰, Proton Rahman¹¹, Frank Behrens¹² and Stefan Siebert¹³, ¹Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ²Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Kyorin University School of Medicine, Tokyo, Japan, ⁵Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, ⁶Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸IQVIA, Budapest, Hungary, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹¹Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ¹²Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ¹³University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Randomized controlled trials have demonstrated the efficacy of IL-23 inhibitors (i) and IL-17i in PsA; however, real-world data on their effectiveness in heterogeneous patient…
Abstract Number: 2013 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Rongping Li⁸, Rongbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), ⁶The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ⁷Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: Acute gouty arthritis(GA) is a common and debilitating condition, especially for patients unsuitable for standard therapy. Firsekibart, previously called Genakumab, is a first-in-class fully…
Abstract Number: 0099 • ACR Convergence 2025
Time course and impact of IL17A on hepatic inflammation and fibrosis in adjuvant induced arthritis
Arthur Dollinger¹, Frédéric Meyer¹, Hélène Martin², Céline Delougeot³, Delphine Weil-Verhoeven¹ and Frank Verhoeven⁴, ¹CHU Besancon, Besancon, France, ²Université Marie et Louis Pasteur, Besancon, France, ³université Marie et Louis Pasteur, Besancon, ⁴CHU de Besançon, Besançon, Franche-Comte, France
Background/Purpose: The management of spondyloarthritis. (SpA) includes controlling disease activity as well as comorbidities such as metabolic syndrome. Metabolic syndrome can be associated with metabolic…
Abstract Number: 0653 • ACR Convergence 2025
In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at their Clinical Dose Regimens
May-Linda Lepage¹, Patrick Nolain¹, Céline Cottereaux¹, Emilie Lagoutte¹, Justine Dao¹, Adrien Cosson¹, Laetitia Furio¹, Willem Hettema², Chantal Tasset³, Roland Blanqué¹, Isabelle Parent¹ and René Galien¹, ¹Galapagos SASU, Paris, France, ²Galapagos B.V., Leiden, Netherlands, ³Galapagos NV, Mechelen, Belgium
Background/Purpose: Tyrosine kinase 2 (TYK2), a Janus kinase (JAK) family member, is attracting a lot of interest as a new target to treat patients with…
Abstract Number: 2014 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Rongping Li⁸, Rongbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), ⁶The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ⁷Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: Approximately 70% of adults with gout have CKD (Chronic Kidney Disease) ≥stage 3 (i.e estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2), significantly restricts treatment…
Abstract Number: 0134 • ACR Convergence 2025
Neutrophil Gasdermin D Pores as Potential Therapeutic Targets in APS-Associated Thromboinflammation
NaveenKumar Somanathapura¹, Thalia Newman¹, Chao Liu², Srilakshmi Yalavarthi³, Cyrus Sarosh⁴, Jacqueline Madison¹, Ajay Tambralli¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann arbor, MI, ²University of Michigan, Superior Charter Twp, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ⁴University of Michigan, Temperance, MI
Background/Purpose: Emerging evidence implicates neutrophil activation and neutrophil extracellular trap (NET) formation (i.e., NETosis) in amplifying APS-associated thromboinflammation. Gasdermin D (GSDMD), a substrate of inflammatory…
Abstract Number: 0909 • ACR Convergence 2025
Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
Marcus Hines¹, Timothy Borbet² and Sergei Koralov², ¹New York University Grossman School of Medicine, New York, NY, ²NYU Langone Medical Center, New York
Background/Purpose: The microRNA(miR)29 family is encoded by two separate loci, the miR29ab1 and miR29b2c alleles. We have previously shown that the microRNA(miR)29 family regulates the…
Abstract Number: 2043 • ACR Convergence 2025
Renal Outcomes of Long-term Canakinumab in Patients with Adult Familial Mediterranean Fever (FMF) and Biopsy-Confirmed AA Amyloidosis
Büşra Fırlatan Yazgan¹, Gözde Sevgi Kart bayram¹, Buğu Bulat¹, Levent Kılıç¹, Tolga Yildirim², Umut Kalyoncu¹, Şule Apraş Bilgen¹, Ali İhsan Ertenli¹, Seref Rahmi Yilmaz² and Omer Karadag³, ¹Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²Division of Nephrology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
Background/Purpose: Canakinumab, an interleukin-1β inhibitor, has demonstrated efficacy in treating colchicine-resistant/intolerant familial Mediterranean fever (FMF). This study aims to assess the efficacy and safety of…
Abstract Number: 0242 • ACR Convergence 2025
Contemporary Recurrent Pericarditis Management – Real-world Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept
Brittany Weber¹, Paul Cremer², Michael Garshick³, Sushil Allen Luis⁴, Ajit Raisinghani⁵, Vidhya Parameswaran⁶, Allison Curtis⁶, Allan Klein⁷ and John Paolini⁶, ¹Brigham and Women's Hospital, DEDHAM, MA, ²Cleveland Clinic, Shaker Heights, OH, ³NYU Langone Health, Tenafly, NJ, ⁴Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, ⁵Division of Cardiology, Department of Medicine, Sulpizio Cardiovascular Center, University of California San Diego, San Diego, CA, ⁶Kiniksa Pharmaceuticals, LEXINGTON, MA, ⁷Cleveland Clinic, Cleveland, OH
Background/Purpose: Recurrent pericarditis (RP) is a chronic autoinflammatory disease (mediated by IL-1) that requires long-term treatment, and selection of therapy is guided by multiple factors.…
Abstract Number: 0979 • ACR Convergence 2025
IL-23 upregulates IFN-γ secretion in Th17.1, but not in Th17 or classical Th1 cells
Bennie van Heeswijk¹, Wida Razawy², Anne-Marie Mus-Otten³, Patrick Asmawidjaja², Pieter Leenen² and Erik Lubberts⁴, ¹Erasmus MC, University Medical Center Rotterdam, Hoofddorp, Netherlands, ²Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands, ³Erasmus medical center, Rotterdam, Netherlands, ⁴Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: Interleukin-23 (IL-23) is a key cytokine in the pathogenesis of psoriatic diseases, as demonstrated by the clinical success of IL-23-targeted therapies. Monocytes are a…
Abstract Number: 2151 • ACR Convergence 2025
Real-World Experience with IL-1 Blockade in Children with Undifferentiated Systemic Autoinflammatory Diseases (uSAIDs)
Maryam Ashoor¹, Kosar Asna Ashari², Kyle McBrearty², Joyce Chang³, Jonathan Hausmann⁴ and Fatma Dedeoglu², ¹Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Brookline, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, ⁴Boston Children's Hospital, bosto, MA
Background/Purpose: Systemic Autoinflammatory Diseases (SAIDs) are a group of rare disorders caused by dysregulation of the innate immune system. Over 50 genes have been identified…
Abstract Number: 0267 • ACR Convergence 2025
Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab
NUR BARLAS¹, Sait Barlas¹ and Emre Adalier², ¹Florida State University College of Medicine, Cape Coral, ²University of Pavia School of Medicine & Surgery, Pavia, Italy
Background/Purpose: Interleukin-17 (IL-17) and interleukin-23 (IL-23) inhibitors have revolutionized treatment for psoriatic arthritis, axial spondyloarthritis, and moderate-to-severe plaque psoriasis. IL-17 inhibitors block the pro-inflammatory cytokine…

1
2
3
…
14
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].